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INTRODUCTION
The demand for dietary supplements has continually in-
creased in recent years as the concept of ‘well being’ widely
spread in Korea. The market value for dietary supplements in
Korea was approximately 600 billion won (600 million USD)
in year 2005 (1), and personal spending was approximately
950,000 won (950 USD) per year in 2005 (2). One of the lead-
ing products in Korea’s dietary supplements market is aloe.
Aloe has been purported to have positive effects on wound
healing, recovery from burn injury, cell growth, and immune
modulation. However, cases of aloe-induced toxic hepatitis
have been reported since 2005. In particular, there have been
one each in Germany (3), Turkey (4), and USA (5). In Switzer-
land (6), 10 cases of hepatotoxicity associated with dietary sup-
plements from Herbalife
� products were reported. Although
2 of those 10 cases took aloe preparation, the causality assess-
ment between aloe and toxic hepatitis could not be done due
to multiple Herbalife
� products. 
We report 3 cases of aloe-induced toxic hepatitis in Korea.
CASE REPORTS
Case 1
A 57-yr-old female patient with a 2 month history of dys-
pepsia was presented to our department. Past medical histo-
ry and family history did not reveal any significant disease.
She also used drugs for arthralgia intermittently for several
years. She did not take any alcohol. She had taken aloe tablets
containing 250 mg of an extract of Aloe arborescens and 28.5
mg of an extract of Aloe vera (Fig. 1) for about 6 months prior
to the admission. On admission, the patient’s physical exam-
ination was normal. 
Laboratory abnormalities included aspartate aminotrans-
ferase (AST) 331 IU/L, alanine aminotransferase (ALT) 565
IU/L, alkaline phosphatase (AP) 309 IU/L. Anti-HAV IgM,
anti-HCV, HCV PCR, and anti-HEV IgM were negative.
Anti-HBs IgG was positive. There was no serologic evidence
for recent infections with cytomegalovirus (CMV), Epstein-
Barr-virus (EBV), or herpes simplex virus (HSV). Autoim-
mune markers were all negative. Abdominal ultrasonogra-
phy showed reduced echogenicity of liver. Dilatation of intra-
or extrahepatic bile ducts was absent. Liver biopsy revealed
moderate portal infiltrates consisting of eosinophilis, neutro-
phils, and monocytes. There were inflammatory cell infiltra-
tion and acidophil body on the hepatic lobule. There was no
bile stasis (Fig. 2).
Aloe tablets was immediately discontinued. ALT was highest
(926 IU/L) on the 12th day of admission and gradually dec-
reased to 452 IU/L on the 25th day of admission. ALT as well
as total bilirubin gradually returned to normal level over sever-
al weeks (Fig. 3). Using the Roussel Uclaf Causality Assess-
ment Method for determining drug hepatotoxicity (RUCAM)
scale, this case was scored as ‘probable’ (Table 1). The type of
liver injury was determined as ‘hepatocellular’ since R ratio
(serum activity of ALT/serum activity of AP) was 10 (7). 
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Aloe-induced Toxic Hepatitis
Aloe has been widely used in phytomedicine. Phytomedicine describes aloe as a
herb which has anti-inflammatory, anti-proliferative, anti-aging effects. In recent years
several cases of aloe-induced hepatotoxicity were reported. But its pharmacokinet-
ics and toxicity are poorly described in the literature. Here we report three cases
with aloe-induced toxic hepatitis. A 57-yr-old woman, a 62-yr-old woman and a 55-
yr-old woman were admitted to the hospital for acute hepatitis. They had taken aloe
preparation for months. Their clinical manifestation, laboratory findings and histo-
logic findings met diagnostic criteria (RUCAM scale) of toxic hepatitis. Upon discon-
tinuation of the oral aloe preparations, liver enzymes returned to normal level. Aloe
should be considered as a causative agent in hepatotoxicity. 
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Case 2
A 62-yr-old female patient was presented to our department
with a week history of fatigue. Past medical history and fam-
ily history did not reveal any significant disease. The patient
did not take any alcohol or durgs. She had taken aloe pow-
der containing 420 mg of an extract of Aloe vera (Fig. 1B)
for about 3 months prior to the admission. Physical exami-
nation revealed jaundice on her sclera. She was the sales per-
son of the aloe product she was taking.
Laboratory abnormalities included AST 1,477 IU/L, ALT
1,564 IU/L, total bilirubin 14.64 mg/dL. Anti-HAV IgM,
anti-HCV, HCV PCR, and anti-HEV IgM were negative.
Anti-HBs IgG was positive. IgM antibody for HSV was in
trace, IgM antibody for CMV was negative. Abdominal ultra-
sonography was normal. Liver biopsy revealed severe portal
and lobular infiltrates consisting of neutrophils and mono-
cytes. There were several acidophilic bodies and ballooning
cell change in hepatic lobule. There were bile-stasis and bile
stained Kupffer cells (Fig. 2B).
Aloe extract was immediately discontinued. ALT gradu-
ally decreased to 452 IU/L which was lower than half of the
peak value on the 17th day of admission. When she was dis-
charged ALT and AST were normal. We explained to her
about the aloe-induced hepatotoxity and advised not to take
Fig. 1. Preparation of aloe which the patient had taken. (A) Container bottle and tablets. (B) Packs of aloe extract.
A B
Fig. 2. Histopathological findings of the liver. (A) The portal area and lobular area show inflammatory cell infiltration (H&E, ×100). (B) The
acidophilic body and ballooning cell change are noted (H&E, ×200).
A B
Fig. 3. Case 1. Upon discontinuation of the oral aloe preparation,
liver enzymes returned to normal level. 
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it anymore. However, the patient started taking the same aloe
extract again 1 month after her discharge from the hospital.
A month later, follow-up liver function test showed AST 477
IU/L, ALT 785 IU/L, and AP 165 IU/L (Fig. 4). Since a hepati-
tis recurred after re-challenge of aloe extract, we could confirm
her diagnosis as aloe-induced toxic hepatitis. The RUCAM
scale was scored as ‘definite’ (Table 1). The type of liver injury
was determined as ‘hepatocellular’ since R ratio was 39. 
Six months later, the patient was presented to our depart-
ment with a 2 week history of jaundice. Laboratory test showed
AST 752 IU/L, ALT 1,135 IU/L, AP 243 IU/L and total biliru-
bin 15.81 mg/dL. We recommended admission, but she re-
fused to be admitted and she never visited our hospital again. 
Case 3
A 55-yr-old female patient was presented to our depart-
ment with a 3 month history of epigastric discomfort. Past
medical history and family history did not reveal any signif-
icant disease. The patient did not take any alcohol or drugs.
She had taken aloe extracts (Fig. 1) for about 5 months prior
to the admission. On admission, the patient’s physical exam-
ination was normal except mild tenderness on epigastric area.
Laboratory abnormalities included AST 344 IU/L, ALT
666 IU/L, AP 298 IU/L. Anti-HAV IgM, anti-HCV, HCV
Case 1 Case 2 Case 3
Temporal relationship of start of drug to start of illness
Initial treatment >90 days +1 Initial treatment 5-90 days +2 Initial treatment >90 days +1
From cessation of drug ≤15 days 0 From cessation of drug ≤15 days +1 From cessation of drug ≤15 days 0
Course
ALT decreases ≥50% from peak  +2 ALT decreases ≥50% from peak +2 ALT decreases ≥50% from peak +3
within 30 days within 30 days within 8 days
Risk factors
No alcohol 0 No alcohol 0 No alcohol 0
Age ≥55 yr +1 Age ≥55 yr 0 Age ≥55 yr +1
Concomitant drugs
None 0 None 0 None 0
Number of nondrug causes
HAV, HBV, HCV, biliary obstruction,  +2 HAV, HBV, HVC, biliary obstruction, +1 HAV, HBV, HVC, biliary obstruction, +1
alcoholism, recent hypotension,  alcoholism, recent hypotension,  alcoholism, recent hypotension,
CMV, EBV, HSV excluded CMV infection excluded excluded
Previous information on hepatotoxicity of the drug in question
Published case reports but not  +1 Published case reports but not in  +1 Published case reports but not  +1
in package label package label in package label
Rechallenge
Not done 0 Positive +2 Not done 0
Probable 7 Definite 9 Probable 7
Table 1. RUCAM score of these cases
Fig. 4. Case 2. Upon discontinuation of the oral aloe preparation,
liver enzymes returned to normal level. After re-challenge (arrow),
liver enzymes go up again.
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Fig. 5. Case 3. Upon discontinuation of the oral aloe preparation,
liver enzymes returned to normal level. 
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PCR, and anti-HEV IgM were negative. Anti-HBs IgG was
positive. Autoimmune markers were negative. Abdominal
ultrasonography showed increased echogenicity of liver. Dila-
tation of intra- or extrahepatic bile ducts was absent. 
Aloe extract was immediately discontinued. ALT was high-
est (666 IU/L) on the 2nd day of admission, and gradually
decreased. ALT was 484 IU/L on her discharge (on the 5th
day of admission). After 4 days, she visited our department
for follow-up. Liver function test was normal at that time (AST
29 IU/L, ALT 11 IU/L, AP 190 IU/L) (Fig. 5). The RUCAM
scale was scored as ‘probable’ (Table 1). The type of liver injury
was determined as ‘hepatocellular’ since R ratio was 11.
DISCUSSION
The major driving force for the growth of the dietary sup-
plements market is the perception that ‘they are safe because
they are natural’. However, the recently reported cases of hep-
atotoxicity induced by natural substances (8) indicate that
natural substances may not be entirely safe. 
There are about 400 species of aloe. Among them, partic-
ularly aloe vera has been used in phytomedicine. There have
been positive reports on aloe vera as anti-inflammatory, anti-
cancer, analgesic, anti-aging as well as liver protective. But,
clinical effectiveness of aloe vera was not sufficiently defined
because there were no large and randomized studies (9). In
1994, Korea’s National Institute of Safety Research conducted
an experiment on the efficacy and toxicity of aloe (10). There
was no difference of natural killer cell activity between the
aloe vera gel treated and control animals. To observe the tox-
icity of aloe gel, rats were given the high dose aloe orally. Any
adverse effects were not detected in hematological test, serum
biochemistry, and histopathological examination. 
There are no specific tests or diagnostic criteria for herb-
induced hepatic injury. Careful history taking, laboratory find-
ing, and histopathology are used to diagnose it. The best way
to determine causing agent is re-challenging. But it is not
ethical and not applicable. Instead, the RUCAM scale is used
(7, 11).
Since patients usually do not regard dietary supplements as
‘real’ medicine, they may fail to mention it when physicians
query medication history. Physicians should keep in mind that
dietary supplements can be the cause of hepatotoxicity when
querying medication history, and should educate the lay public.
There are three types of acute liver injury by drug or herb
(12): hepatocellular, cholestatic, and mixed type. Our cases
are characterized as hepatocellular; there is a predominant ini-
tial elevation of the ALT level. There are two proposed patho-
geneses of drug induced liver disease (13): direct toxicity and
idiosyncratic mechanism. It is more likely that an idiosyncrat-
ic immunological mechanism (hypersensitivity) is responsi-
ble for the cases. A role for hypersensitivity is further support-
ed by the presence of eosinophilic granulocytes in the peri-
portal fields seen in the biopsy. Hypersensitivity to aloe has
been described in humans (14), and the patch test or aller-
gic skin test showed positive results (15).
Herb induced liver injury is an important problem in clini-
cal setting, because it can be an etiology of undiagnosed acute
hepatitis. However, there are few available data about the inci-
dence and clinical manifestation of dietary supplements such
as aloe. Our cases emphasize that physicians should consider
various dietary supplements as causative agents for hepatotox-
icity.
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